ALEC
Alector, Inc.
$2.10
-13.93%
2026-05-08
About Alector, Inc.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Key Fundamentals
Forward P/E
-2.45
EPS (TTM)
$-1.39
ROE
-181.6%
Revenue Growth (YoY)
-88.5%
Profit Margin
0.0%
Debt/Equity
118.22
Price/Book
8.09
Beta
0.65
Market Cap
$249.8M
Avg Volume (10D)
427K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.74
60D Low
$1.84
Avg Volume
701K
Latest Close
$2.10
Get breakout alerts for ALEC
Sign up for Breakout Scanner to receive daily notifications when ALEC triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Alector, Inc. (ALEC) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ALEC daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ALEC operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.